Bu dergideki yayınlar

5 →
  • ArticleAçık Erişim2020
    INTERACTION OF APELIN, ELABELA AND NITRIC OXIDE IN SCHIZOPHRENIA PATIENTS; [INTERAKCIJA APELINA, ELABELA I AZOT OKSIDA KOD PACIJENATA KOJI BOLUJU OD ŠIZOFRENIJE]

    Catak, Zekiye; Kaya, Hilal; Kocdemir, Esra; Ugur, Kader; Guzel, Saadet Pilten; Yardim, Meltem; Sahin, Ibrahim; Agirbas, Esra Piril; Aydin, Suleyman

    Background: Apelin (APLN), elabela (ELA), and nitric oxide (NO) have effects on physiological and behavioural properties in biological systems. This study was designed to determine APLN, ELA and NO levels in schizophrenia patients and assess whether these molecules are of diagnostic value. Methods: A total of 33 schizophrenic patients and 32 ageand sex-adjusted healthy participants were included in the study. ELA, APLN and NO levels were measured using ELISA methods. Results: Although the ELA and NO levels of the patients were lower than the control group, APLN levels were higher (p = 0.039, p = 0.019, p = 0.048, respectively). There was a significant negative correlation between APLN levels and triglyceride (TG) and body mass index (BMI) levels (r =-0.426, p = < 0.001 and r =-0.330, p = 0.007, respec tively). Respectively, the areas under the receiver-operating characteristic (ROC) curves of the ELA/APLN, ELA/NO and APLN/NO ratios were 0.628, 0.590 and 0.709, 95% confident intervals (CI): 0.491–0.764, 0.450–0.730 and 0.579–0.840. Conclusions: Decreased levels of ELA and NO and increased APLN levels in schizophrenia suggest that these molecules may be involved in its etiopathology. The APLN/NO ratio also seems to show promise in the diagnosis of the disease and may be used in future.

    RDL Kalıcı Kaydıİncele
  • ArticleAçık Erişim2019
    A novel biomarker renalase and its relationship with its substrates in schizophrenia

    Catak, Zekiye; Kocdemir, Esra; Ugur, Kader; Yardim, Meltem; Sahin, Ibrahim; Kaya, Hilal; Aydin, Suleyman

    Schizophrenia, particularly the form related to excessive dopamine (DA), is a chronic psychotic disorder affecting millions of people worldwide. Renalase metabolizes its catecholamine (CA) substrates, including DA, suggesting that there might be an association between renalase levels and schizophrenia occurrence. Therefore, the current study aimed to evaluate the renalase and CA levels in the serum of patients with schizophrenia. The study was conducted with thirty-three schizophrenia patients and an age-and gender-matched group of thirty-one controls. Renalase and CA levels were measured by using an enzyme-linked immunosorbent assay (ELISA). Renalase levels were significantly lower in the schizophrenia patients than in the control group (p<0.05), whereas DA levels were significantly higher (p<0.05). The epinephrine (Epi) levels of both groups were similar (p=0.186), while the norepinephrine levels in patients with schizophrenia were significantly lower than those in the control group (p<0.05). The areas under the curves for the renalase-dopamine, renalase-norepinephrine and renalase-epinephrine ratios were 0.805, 95% confidence interval (CI): 0.699-0.912 (p<0.001); 0.726, 95% CI: 0.594-0.859 (p=0.032); and 0.656, 95% CI: 0.520-0.791 (p=0.02). The high DA levels in patients with schizophrenia might be due to low renalase levels. Renalase enzyme levels may play a substantial role in the pathophysiology of schizophrenia. Thus, this enzyme might be a new future target for the treatment and diagnosis of schizophrenia after intrabrain renalase and DA dynamics have been further evaluated.

    RDL Kalıcı Kaydıİncele
  • ArticleYayıncıda açık erişim2018
    Myo-inositol oxygenase as a novel marker in the diagnosis of acute kidney injury

    Mertoglu, Cuma; Gunay, Murat; Gurel, Ali; Gungor, Mehmet

    Background: Due to the lack of diagnostic efficiency of serum creatinine in acute kidney injury (AKI), there is a pressing need to develop novel diagnostic markers. Therefore, in this study, we evaluated myo-inositol oxygenase (MIOX), neutrophil gelatinase-Associated lipocalin (NGAL) and cystatin C in terms of their applicability in the diagnosis of AKI. Methods: We enrolled a total of 39 AKI patients and 38 healthy controls in the study. We compared the levels of serum MIOX, NGAL and cystatin C between the two groups. Results: We found that the concentrations of serum creatinine, blood-urea nitrogen, MIOX and cystatin C were higher in the AKI group. According to the receiver operating characteristic analysis, the area under the curve (AUC) values were 0.694 (95% CI 0.579-0.794) for MIOX and 0.976 (95% CI; 0.912-0.997) for cystatin C. For MIOX, when the cut-off concentration was set to 77.3 pg/mL, the diagnostic sensitivity and specificity were found to be 53.8% (95% CI; 37.2-69.9) and 81.5 (95% CI; 65.7-92.3), respectively. For cystatin C, at the cut-off value of 14 mg/L, the diagnostic sensitivity and specificity were 94.8% (95% CI; 82.7-99.4) and 94.7 % (95% CI 82.3-99.4), respectively. Conclusions: The measurement of serum MIOX and cystatin C levels is valuable for the diagnosis of AKI. Further research is needed for the evaluation of the potential use of MIOX as a kidney-specific enzyme in the early diagnosis of AKI.

    RDL Kalıcı Kaydıİncele
  • Review ArticleAçık Erişim2012
    The past and present of paraoxonase enzyme: Its role in the cardiovascular system and some diseases

    Aydin, Suleyman; Sahin, Ibrahim; Aydin, Suna; Aksoy, Aziz; Citil, Cihan

    Although paraoxonase is synthesized in many tissues including the heart, colon, kidneys, lungs, small intestines and brain, its major locus of synthesis is the liver. PON1 is in close association with apolipoproteins and protects LDL against oxidation. It was reported that PON1 quantities dropped to 40 times lower than normal in cardiovascular diseases and diseases like diabetes, ulcerative colitis, Crohn's disease, chronic renal failure, SLE, Behcet's disease, cancer, hepatitis B, obesity, metabolic syndrome, Alzheimer's and dementia. It is speculated that the concerning decline in serum PON1 amount results from single nucleotide polymorphism in the coding (Q192R, L55M) and promoter (T-108C) sites of the PON1 gene. Additionally, circulating amounts of PON1 are affected by vitamins, antioxidants, fatty acids, dietary factors, drugs, age and lifestyle. This collection attempts to review and examine the past and present studies of paraoxonase and its relation with the cardiovascular system and some relevant diseases.

    RDL Kalıcı Kaydıİncele
  • ArticleAçık Erişim2010
    Ghrelin, nitrite and paraoxonase/arylesterase concentrations in cement plant workers

    Aydin, Suleyman; Aydin, Suna; Croteau, Gerry A.; Sahin, Íbrahim; Citil, Cihan

    Occupational cement dust exposure has been associated with an increased risk of liver abnormalities, pulmonary disorders, and carcinogenesis. Decreased antioxidant capacity and increased plasma lipid peroxidation have been posed as possible causal mechanisms of disease. Accordingly, this study examined the serum paraoxonase (PON1) arylesterase (AE), ghrelin, HDL-C, LDL-C and serum nitrite (NOx) levels in cement dust exposed workers. Twenty-eight volunteer male cement plant workers and 30 volunteer control male workers, aged 29-54 years, participated. The concentrations of serum PON1, AE, NOx, ghrelin, and HDL-cholesterol and LDL-cholesterol were measured in both groups. PON-1, AE, ghrelin and HDL-cholesterol were lower in the cement plant workers than in controls. Serum nitrite (NOx), and LDL-C levels in cement plant workers were higher (p<0.05) than in the control group workers. No correlation was observed between the serum levels of HDL-cholesterol and PON1 and between HDL-cholesterol and ghrelin. A weak negative correlation was detected between the serum ghrelin and NOx. The study results strongly suggest that HDL-paraoxonase, AE, ghrelin, HDL-C, and high NOx, and LDL-C levels may have a role in disease involving oxidative damage. However, some studies are necessary to address the association between occupational dust exposure and respiratory symptoms.

    RDL Kalıcı Kaydıİncele
Tam Kayıt
AlanDeğerDil
creativeworkseries.issn1452-8258
creativeworkseries.issn1452-8266
dc.date.accessioned2026-10-20T15:39:58.996700804Z
dc.date.available2026-10-20T15:39:58.996700804Z
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/24457
dc.publisherSociety of Medical Biochemists of Serbia
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleJournal of Medical Biochemistry
dspace.entity.typeJournal